Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.7252W HIGH $4.50
Volume
53.81 K
Value Traded
20.05 K
Short % Float
0.25%
-1.19%Week
-49.62%1 Month
-62.29%3 Month
-73.45%6 Month
-99.49%5 Year
-99.73%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.00 M
EPS (TTM)
-1.58
P/E Ratio
-
Ent. Value
1.87 M
Total Shares
2.54 M
Float Shares
2.43 M
Insiders
17.06%
Institutions
3.09%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
TCRT Catalyst Timeline
Dated clinical, regulatory and corporate events for Alaunos Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Alaunos Therapeutics, Inc.
620Total events
3Upcoming
93Tier-1 (high impact)
2009 to 2026Coverage
Upcoming catalysts 2
TBD
T2IND Submission
Subscribe to view catalyst details
TBD
T3IND Enabling Complete
Subscribe to view catalyst details
Event history 50
▼Equity OfferingCorporate
Pricing of registered direct offering of common stock and pre-funded warrants for ~$1.12M gross proceeds
▲Preclinical PoCALN1003Preclinical
Integrated preclinical readout for ALN1003 in DIO mouse studies
obesity and related metabolic disorderssource ↗
●Oral PresentationALN1003Presentation
Investor presentation published with integrated preclinical data
obesity and related metabolic disorderssource ↗
▲Preclinical PoCALN1003Preclinical
Preclinical data for ALN1003 in DIO mouse models showing effects on insulin-resistance-related biomarkers and liver histology
metabolic syndromesource ↗
▼Runway Guidance UpdateCorporate
Cash runway extends into Q2 2026; company intends to pursue additional financing
▲Preclinical PoCALN1003Preclinical
Positive preclinical proof-of-concept data for ALN1003 in DIO mouse models
obesity and related metabolic disorderssource ↗
▼Equity OfferingCorporate
Registered direct offering of 610,399 shares at $3.36 per share for gross proceeds of $2.0 million
▲Topline ReadoutClinical Data
Phase 1/2 TCR-T Library trial data: 13% ORR, 87% DCR, one partial response
solid tumors (pancreatic, colorectal, non-small cell lung cancer)source ↗
▲Interim AnalysisTrial
Interim clinical data from TCR-T Library Phase 1/2 trial: 83% disease control rate in evaluable patients
metastatic, refractory solid tumorssource ↗
▼Trial DiscontinuedTrial
Wind down of TCR-T Library Phase 1/2 trial
metastatic, refractory solid tumorssource ↗
◆Pipeline PrioritizationCorporate
Strategic reprioritization to focus on hunTR TCR discovery platform
●Runway Guidance UpdateCorporate
Cash runway guidance: sufficient to fund operations into Q4 2023
▼Program DiscontinuationCorporate
Company will not pursue further development of clinical programs
solid tumorssource ↗
◆Timing GuidancePresentation
Interim data update on multiple new patients expected in Q3 2023
solid tumorssource ↗
◆Topline ReadoutClinical Data
Interim data update on multiple new patients expected in Q3 2023
solid tumorssource ↗
◆Oral PresentationPresentation
Presentation at 2nd Hawaii Global Summit on Thoracic Malignancies
solid tumorssource ↗
◆Poster PresentationPresentation
Poster presentation at ASCO 2023 on Safety and Efficacy of Sleeping Beauty TCR-T Cells
solid tumors (non-small cell lung, colorectal, endometrial, pancreatic, ovarian, bile duct cancers)source ↗
◆Poster PresentationPresentation
Poster presentation of early translational data from first three patients at ASCO 2023
solid tumorssource ↗
▲Partnership / LicenseCorporate
Amended exclusive license agreement with Precigen in April 2023
◆IND SubmissionmbIL-15IND
IND filing for mbIL-15 TCR-T program anticipated in H2 2023
solid tumorssource ↗
◆Enrollment UpdateTrial
Interim data update expected by mid-2023
solid tumors (KRAS, TP53, EGFR hotspot mutations)source ↗
◆Timing GuidancePresentation
Recommended Phase 2 dose anticipated by year-end 2023
solid tumorssource ↗
▲Manufacturing MilestoneCMC / Inspection
Implementation of cryopreserved product expected in H1 2023
◆Platform ValidationPreclinical
Expanded hunTR TCR discovery platform throughput; expect to add three new TCRs in 2023
Past FDA Catalysts and PDUFA Decisions
How TCRT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2022-12-31 | TCR-T Library (non-viral Sleeping Beauty TCR-T cells) | Phase 1/2 data readout | Phase 1/2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D25 / 100
Pipeline Score
$1M
Pipeline Value
Overvalued
Valuation Signal
7
Drugs Scored
0.5x
rNPV / MCap
Top 83%
Micro Cap(rank 548 of 660)
Percentile Rank
Alaunos Therapeutics, Inc. faces pipeline headwinds (25/100), with $1.5B risk-adjusted pipeline value, led by Darinaparson in Multiple Myeloma (Phase 2), but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Darinaparson Small moleculeCompletedNCT00423644 | Multiple Myeloma | Phase 2 | COMPLETED | 17 | Dec 21, 2008 |
Clinical Trial Results
Readouts, endpoints and source filings for every TCRT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ALN1003 | obesity and related metabolic disorders | 2026-03-02 | body weight change: -12.9% (p<0.0001) on Day 34; body weight change 48 days: -10.3% (p<0.0001); food consumption: 347.5 g/cage vs 425.0 g/cage; nominal p<0.05; liver weight reduction: 43% (p<0.0001); liver weight percentage change: 39% (p<0.0001); ALT reduction: lower ALT (p<0.0001); AST reduction: lower AST (nominal p<0.0001); ALP reduction: lower ALP (p<0.0001); total bilirubin trend: nominal p=0.058Read More | Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic DisordersRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Weis HolgerOfficer (Chief Executive Officer) | Grant/Award | 3,880 16,552 held | $2.26 | 06/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TCRT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Boxer Capital Management, LLC | 0 % | 144.00 K | 1.10 M | -26.67% ( -400.00 K) |
TCRT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TCRT ranks across every disease it competes in
Competitive Position is a premium feature
See how TCRT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTCRT News
TCRT▼ -25%on this news
Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules
Alaunos Therapeutics, Inc. has announced a registered direct offering of 380,469 shares of common stock priced at $1.46 per share, aiming for gross proceeds of approximately $1.12 million. The offering is set to close around September 21, 2026, pending customary conditions. The funds will primarily be used for working capital and corporate needs.
Read more →TCRT▲ +13.9%on this news
Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study
Alaunos has reported new preclinical data on ALN1003, indicating a statistically significant reduction in liver weight after adjusting for body fat percentage in a 48-day DIO mouse study. This finding suggests that the observed reduction in liver weight is not solely attributable to body fat. The results are consistent with earlier data regarding lower liver injury enzymes.
Read more →TCRTAlaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies • ALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, including reductions in body weight an
Alaunos Therapeutics announced the positive findings of its investigational drug ALN1003 in recent preclinical studies involving diet-induced obese mice. The data indicated substantial improvements in metabolic parameters, such as body weight reduction, enhanced insulin sensitivity, and improved liver health. Additionally, the company released a non-confidential investor presentation detailing these results and their implications for future therapeutic approaches. Despite the promising results, the studies were non-GLP, which necessitates careful interpretation of the findings.
Read more →TCRTAlaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models
Alaunos Therapeutics announced preclinical data showing that ALN1003, an investigational oral therapeutic candidate, positively affects insulin-resistance-related biomarkers and liver histology in diet-induced obesity mouse models. Key findings include significantly lower fasting insulin levels and improvements in adipose endocrine markers. These results support ALN1003's continued development as a potential treatment for metabolic syndrome and related conditions. However, the data comes from preclinical studies, emphasizing the need for caution as human trials have not yet been conducted.
Read more →TCRTAlaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders
Alaunos Therapeutics announced promising preclinical data for ALN1003, a non-hormonal oral treatment for obesity. In diet-induced obesity mouse models, ALN1003 demonstrated significant body weight loss and favorable changes in liver health. The company plans to continue preclinical studies and refine manufacturing processes as it moves toward an Investigational New Drug application.
Read more →TCRTAlaunos Therapeutics Announces $2.0 Million Registered Direct Offering
Alaunos Therapeutics announced a registered direct offering of 610,399 shares at $3.36 each, aiming to raise approximately $2 million. The net proceeds will be allocated to its obesity program and general corporate needs. The transaction is expected to close on June 24, 2025, pending customary conditions. This offering is part of a previously filed shelf registration statement.
Read more →TCRT▼ -10.6%on this news
Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives
Alaunos Therapeutics reported its third quarter 2023 financial results, highlighting the exploration of strategic alternatives and the outcomes of its TCR-T Library Phase 1/2 Trial. The trial demonstrated that the T cells were well-tolerated, with one patient achieving a partial response. However, the company announced it would halt further clinical program development due to high costs and a challenging financing environment.
Read more →TCRTAlaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives TCR-T Library Phase 1/2 trial achieved an 83% disease control rate of six evaluable pa
Alaunos Therapeutics reported its financial results for Q2 2023 along with interim clinical data and strategic changes. The company achieved an 83% disease control rate in its TCR-T Library Phase 1/2 trial, although it is winding down this trial to focus on its hunTR TCR discovery platform. A significant workforce reduction of approximately 60% has been announced as part of a cost-saving strategy, while strategic alternatives for the company are being explored, including potential partnerships or acquisitions. Overall, Alaunos aims to reposition itself for future developments despite current challenges.
Read more →TCRT▲ +14.3%on this news
Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies
Alaunos Therapeutics announced its participation in the 2nd Hawaii Global Summit on Thoracic Malignancies, where Dr. Matthew Collinson-Pautz will present on their TCR-T therapy targeting specific mutations in solid tumors. The therapy is currently being evaluated in a Phase 1/2 trial at MD Anderson Cancer Center, focusing on various cancers with specific driver mutations. This summit aims to address advancements in lung cancer treatment.
Read more →TCRT▼ -16.6%on this news
Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting
Alaunos Therapeutics announced it will present early data from its TCR-T Library Phase 1/2 trial at the 2023 ASCO Annual Meeting. The trial has shown promising results, including objective clinical responses in two patients with solid tumors. The therapy demonstrated a favorable safety profile, with no significant toxicities reported. The company plans to provide further updates in the third quarter of 2023.
Read more →TCRTAlaunos Therapeutics Reports First Quarter 2023 Financial Results Actively enrolling patients and manufacturing cryopreserved products for TCR-T Library Phase 1/2 trial; expect to report interim data in the third quarter
Alaunos Therapeutics reported its financial results for Q1 2023 and highlighted the ongoing patient enrollment in its TCR-T Library Phase 1/2 trial, focusing on solid tumor indications. The company anticipates interim data to be shared in Q3 2023 and is enhancing its manufacturing capabilities for better flexibility in patient scheduling. A significant financial step was taken with the prepayment of a loan to Silicon Valley Bank, allowing operations to proceed without debt constraints. However, the company also faced a net loss of $10 million for the quarter, raising concerns about its financial outlook.
Read more →TCRTAlaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023
Alaunos Therapeutics has announced it will report its financial results for the first quarter of 2023 on May 10, 2023. The report will be followed by a conference call aimed at discussing the results and providing corporate updates. The company is recognized for its innovative work in T-cell receptor cell therapy, particularly in targeting solid tumors through advanced clinical trials.
Read more →TCRT▲ +10%on this news· ran to +22% by day 3
Alaunos Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
Alaunos Therapeutics announced a poster presentation at the 2023 ASCO Annual Meeting for its lead TCR-T cell therapy program. The Phase 1/2 trial focuses on patients with specific solid tumors and targeted mutations. The presentation will take place on June 3, 2023, showcasing the safety and efficacy of their innovative therapy.
Read more →TCRTAlaunos Therapeutics Appoints Dr. Robert J. Hofmeister to Board of Directors
Alaunos Therapeutics has appointed Dr. Robert J. Hofmeister to its Board of Directors, replacing Chris Bowden. Dr. Hofmeister, who has extensive experience in T-cell receptor therapies, aims to leverage his expertise to enhance Alaunos' TCR-T Library Phase 1/2 trial. The company is focused on revolutionizing solid tumor treatments.
Read more →TCRTAlaunos Therapeutics to Participate in Upcoming Investor Conferences in April
Alaunos Therapeutics announced its participation in two upcoming investor conferences in April 2023. The events include Cantor's The Future of Oncology Virtual Symposium on April 4 and the 22nd Annual Needham Virtual Healthcare Conference on April 17. The company aims to showcase its advancements in T-cell receptor therapy for solid tumors during these presentations.
Read more →TCRTAlaunos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results Generated cutting-edge translational data demonstrating safety, persistence and functionality of infused TCR-T cells in the tumor microenvi
Alaunos Therapeutics reported its fourth quarter and full year 2022 financial results, highlighting significant advancements in its TCR-T cell therapies. The company has seen positive clinical data and is actively enrolling patients in its TCR-T Library Phase 1/2 trial, expecting to report interim data soon. Alaunos has also made enhancements to its TCR library and manufacturing processes, aiming to optimize production and increase patient enrollment. Despite these advancements, the company reported a net loss of $9.2 million for the fourth quarter, reflecting some financial challenges amidst growth efforts.
Read more →TCRTAlaunos Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023
Alaunos Therapeutics, a clinical-stage oncology-focused cell therapy company, announced it will report its financial results for the fourth quarter and full year ended December 31, 2022, on March 7, 2023. Alongside the financial report, the company will hold a conference call to provide a corporate update, reinforcing its commitment to investor engagement. Alaunos is at the forefront of T-cell receptor therapy, actively working to improve cancer treatment outcomes through advanced TCR programs.
Read more →TCRTAlaunos Therapeutics Highlights Strategic Priorities and Anticipated Portfolio Milestones for 2023
Alaunos Therapeutics has outlined its strategic priorities and anticipated milestones for 2023, highlighting the addition of two new T cell receptors (TCRs) to its library, which is expected to double its addressable market. The company aims to increase patient enrollment in its TCR-T Library Program to advance to Phase 2 and improve manufacturing capabilities for greater efficiency. Additionally, Alaunos is planning to file for an Investigational New Drug (IND) for its mbIL-15 therapy later this year. With a solid cash position, the company is well-prepared for its strategic initiatives.
Read more →About Alaunos Therapeutics, Inc.
Headquarters501 E LAS OLAS BLVD, FORT LAUDERDALE, FL, 33301
BIOPHARMAWATCH ELITE PLUS
Trade the next TCRT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime